S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
NASDAQ:ENVB

Enveric Biosciences Stock Forecast, Price & News

$1.25
+0.07 (+5.93%)
(As of 12/7/2021 04:00 PM ET)
Add
Compare
Today's Range
$1.18
$1.25
50-Day Range
$1.15
$2.11
52-Week Range
$1.03
$15.04
Volume
745,053 shs
Average Volume
3.52 million shs
Market Capitalization
$39.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.63
30 days | 90 days | 365 days | Advanced Chart
Receive ENVB News and Ratings via Email

Sign-up to receive the latest news and ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Enveric Biosciences logo

About Enveric Biosciences

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company is headquartered in Naples, FL.

Headlines

Enveric Biosciences on the Merger with MagicMed
October 15, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENVB
Employees
3
Year Founded
N/A

Sales & Book Value

Annual Sales
$39.92 million
Book Value
$1.76 per share

Profitability

Net Income
$-6.86 million
Pretax Margin
-107.37%

Debt

Price-To-Earnings

Miscellaneous

Free Float
31,058,000
Market Cap
$39.23 million
Optionable
Not Optionable

Company Calendar

Today
12/07/2021
Next Earnings (Estimated)
12/13/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

803rd out of 1,394 stocks

Pharmaceutical Preparations Industry

384th out of 673 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Enveric Biosciences (NASDAQ:ENVB) Frequently Asked Questions

Is Enveric Biosciences a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enveric Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Enveric Biosciences stock.
View analyst ratings for Enveric Biosciences
or view top-rated stocks.

Are investors shorting Enveric Biosciences?

Enveric Biosciences saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 1,520,000 shares, a decline of 22.4% from the October 31st total of 1,960,000 shares. Based on an average daily volume of 3,590,000 shares, the short-interest ratio is presently 0.4 days. Approximately 7.3% of the shares of the stock are sold short.
View Enveric Biosciences' Short Interest
.

When is Enveric Biosciences' next earnings date?

Enveric Biosciences is scheduled to release its next quarterly earnings announcement on Monday, December 13th 2021.
View our earnings forecast for Enveric Biosciences
.

What price target have analysts set for ENVB?

2 Wall Street analysts have issued 1-year price objectives for Enveric Biosciences' shares. Their forecasts range from $6.00 to $7.00. On average, they expect Enveric Biosciences' share price to reach $6.50 in the next year. This suggests a possible upside of 420.0% from the stock's current price.
View analysts' price targets for Enveric Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Enveric Biosciences' key executives?

Enveric Biosciences' management team includes the following people:
  • Joseph Tucker, Chief Executive Officer
  • Avani V. Kanubaddi, Chief Operating Officer
  • Carter J. Ward, Chief Financial Officer
  • Robert G. Wilkins, Chief Medical Officer
  • Peter Facchini, Chief Scientific Officer

What is Enveric Biosciences' stock symbol?

Enveric Biosciences trades on the NASDAQ under the ticker symbol "ENVB."

Who are Enveric Biosciences' major shareholders?

Enveric Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.33%), Renaissance Technologies LLC (2.30%), Geode Capital Management LLC (0.54%), Scotia Capital Inc. (0.44%), Citadel Advisors LLC (0.00%) and Two Sigma Investments LP (0.20%).

Which major investors are selling Enveric Biosciences stock?

ENVB stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc..

Which major investors are buying Enveric Biosciences stock?

ENVB stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Scotia Capital Inc., Citadel Advisors LLC, Two Sigma Investments LP, AdvisorShares Investments LLC, Vident Investment Advisory LLC, Geode Capital Management LLC, and Squarepoint Ops LLC.

How do I buy shares of Enveric Biosciences?

Shares of ENVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enveric Biosciences' stock price today?

One share of ENVB stock can currently be purchased for approximately $1.25.

How much money does Enveric Biosciences make?

Enveric Biosciences has a market capitalization of $39.23 million and generates $39.92 million in revenue each year.

How many employees does Enveric Biosciences have?

Enveric Biosciences employs 3 workers across the globe.

What is Enveric Biosciences' official website?

The official website for Enveric Biosciences is jaypharma.co.

Where are Enveric Biosciences' headquarters?

Enveric Biosciences is headquartered at 4080 MCGINNIS FERRY ROAD SUITE 1306, ALPHARETTA GA, 30005.

How can I contact Enveric Biosciences?

Enveric Biosciences' mailing address is 4080 MCGINNIS FERRY ROAD SUITE 1306, ALPHARETTA GA, 30005. The company can be reached via phone at (239) 302-1707, via email at [email protected], or via fax at 732-243-9254.


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.